Dr. Gillespie obtained B.A. (Biology & Chemistry), M.Sc. (Cytogenetics) and Ph.D. (Immunology & Immunogenetics) degrees at the University of Mississippi, finishing in 1971. Following a NCI F31 postdoctoral fellowship at the University of Kansas Medical Center, he was appointed to the Department of Pathology as Instructor. In 1975, he joined Scripps Clinic and Research Foundation in La Jolla. In 1977, he moved as Assistant Professor of Pathology to the University of North Carolina-Chapel Hill. In 1979, he transferred to the Department of Surgery, Division of Neurosurgery to direct the Brain Tumor Immunology research program. In 1986, Dr. Gillespie came to UAB as tenured Associate Professor of Surgery to direct brain tumor research efforts in the Division of Neurosurgery. He is currently Professor of Surgery with secondary appointments in the Departments of Microbiology and Cell Biology. Dr. Gillespie is Director of the UAB Brain Tumor Specialized Program Of Research Excellence (SPORE), and leader of Brain Tumor Animal Models Core Facility.
Research Interests: Molecular and Viral Therapy of Malignant Primary Brain Tumors
Feature Publications:
1.Radbill AE, Reddy AT, Markert JM, Wyss JM, Pike MM, Akella NS, Bharara N, Gillespie GY. Effects of G207, a conditionally replication-competent oncolytic herpes simplex virus, on the developing mammalian brain. J Neurovirol. 2007 13(2):118-129.
2. Shah AC, Parker JN, Gillespie GY, Lakeman FD, Meleth S, Markert JM, Cassady KA. Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses. Gene Ther. 2007 14(13):1045-1054.
3. Guffey MB, Parker JN, Luckett WS Jr, Gillespie GY, Meleth S, Whitley RJ, Markert JM. Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumors. Cancer Gene Ther. 2007 14(1):45-56.
4. Griguer CE, Oliva CR, Gobin E, Marcorelles P, Gillespie GY. Pharmacologic manipulations of mitochondrial membrane potential (DYm) selectively in glioma cells. J Neurooncol. 2007 81(1):9-20.